Dr. Moskowitz on the ALCANZA Trial in CTCL
4 意见
• 08/09/23
0
0
嵌入
Alison J. Moskowitz, MD, clinical director, Lymphoma Inpatient Unit, Memorial Sloan Kettering Cancer Center, discusses the data that led to the approval of brentuximab vedotin (Adcetris) in patients with cutaneous T-cell lymphoma (CTCL).
显示更多
脸书评论
SORT BY-
热门评论
-
最新评论